What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2026-03-31 compared with 2025-04-11 · 21 added, 71 removed, 4 unchanged (96% of the section changed)

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER

MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

MARKET FOR REGISTRANT’S COMMON

EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

Market for our Common Stock

Our common stock is quoted on the NYSE American under the

symbol “PLAG”.

Approximate Number of Holders of Our Common Stock

As of December 31, 2024, there were 322 stockholders

of record of our common stock.

This does not include the holders whose shares are held in a depository trust in “street” name.

We have not declared or paid cash dividends other

than the payment of a dividend in April 2007 in connection with our reverse merger.

Any future decisions regarding dividends will be made

by our Board of Directors.

We currently intend to retain and use any future earnings for the development and expansion of our business

and do not anticipate paying any cash dividends in the foreseeable future.

Our common stock is quoted on the NYSE

American under the symbol “PLAG”.

Approximate Number of Holders of Our

As of March 31, 2026, there

were 332 stockholders of record of our common stock.

This does not include the holders whose shares are held in a depository trust in

“street” name.

We have not declared or paid

cash dividends other than the payment of a dividend in April 2007 in connection with our reverse merger.

Any future decisions regarding

dividends will be made by our Board of Directors.

We currently intend to retain and use any future earnings for the development and expansion

of our business and do not anticipate paying any cash dividends in the foreseeable future.

Issuances of Unregistered Securities

On May 9, 2019, we and Shanghai Xunyang entered

into a share exchange agreement with Xianning Bozhuang and each of the original shareholders of Xianning Bozhuang.

Such transaction closed

on May 14, 2019.

Pursuant to the share exchange agreement, we issued an aggregate of 1,080,000 shares of common stock of the Company to

the Sellers in exchange for the transfer of all of the equity interest of Xianning Bozhuang to Shanghai Xunyang.

On June 17, 2019, the Company entered into a securities

purchase agreement, pursuant to which five individuals residing in the PRC agreed to purchase an aggregate of 1,300,000 shares of the

Company’s common stock, par value $0.001 per share, for an aggregate purchase price of $5,460,000, representing a purchase price

of $4.20 per share.

The transaction closed on June 19, 2019.

On January 26, 2021, the Company entered into a

securities purchase agreement, pursuant to which three individuals residing in the PRC agreed to purchase an aggregate of 2,700,000 shares

of the Company’s common stock, par value $0.001 per share, for an aggregate purchase price of $6,750,000, representing a purchase

price of $2.50 per share.

The transaction closed on January 29, 2021.

On March 9, 2021, the Company entered into a share

exchange agreement with Jilin Chuangyuan and each of the original shareholders of Jilin Chuangyuan.

Pursuant to the share exchange agreement,

we issued an aggregate of 3,300,000 shares of common stock of the Company to the Sellers in exchange for the transfer of 75% of the equity

interest of Jilin Chuangyuan.

On April 24, 2021, the Company entered into a securities

purchase agreement, pursuant to which three individuals residing in the PRC agreed to purchase an aggregate of 4,000,000 shares of the

Company’s common stock, par value $0.001 per share, for an aggregate purchase price of $7,600,000, representing a purchase price

of $1.90 per share.

The transaction closed on May 20, 2021.

On July 15, 2021, the Company entered into a share

exchange agreement with Anhui Ansheng and each of the original shareholders of Anhui Ansheng.

Pursuant to the share exchange agreement,

we issued an aggregate of 4,800,000 shares of common stock of the Company to the Sellers in exchange for the transfer of 66% of the equity

interest of Anhui Ansheng.

On December 9, 2021, the Company entered into a

share exchange agreement with Shandong Yunchu and each of the original shareholders of Shandong Yunchu.

Pursuant to the share exchange

agreement, we issued an aggregate of 5,900,000 shares of common stock of the Company to the Sellers in exchange for the transfer of all

of the equity interest of Shandong Yunchu.

On January 13, 2022, the Company entered into a

securities purchase agreement, pursuant to which three individuals residing in the PRC agreed to purchase an aggregate of 7,000,000 shares

of the Company’s common stock for an aggregate purchase price of $7,000,000, representing a purchase price of $1.00 per share.

transaction closed on January 14, 2022.

On April 8, 2022, the Company

entered into a share exchange agreement with Allinyson and each of the original shareholders of Allinyson.

Pursuant to the share exchange

agreement, we issued an aggregate of 7,500,000 shares of common stock of the Company to the shareholders of Allinyson in exchange for

the transfer of all of the equity interest of Allinyson.

On May 19, 2022, the Company

entered into a Securities Purchase Agreement with two investors residing in the People’s Republic of China, pursuant to which the

purchasers agreed to invest an aggregate of $4,100,000 in the Company in exchange for an aggregate of 10,000,000 shares of the Company’s

common stock, representing a purchase price of $0.41 per share.

The transaction closed on May 27, 2022.

On July 15, 2022, the Company

entered into a share exchange agreement with Xiangtian Energy and the shareholder of Xiantian Energy.

Pursuant to the Share Exchange Agreement,

in exchange for the acquisition of the 30% equity interest of Xiangtian Energy, the Company issued an aggregate of 12,000,000 shares of

common stock, par value $0.001 per share, of the Company to the Seller.

During the fiscal year ended December 31, 2025, the Company did not

sell any equity securities that were not registered under the Securities Act of 1933, as amended.

Accordingly, no disclosure is required

pursuant to Item 701 of Regulation S-K.

Securities Authorized for Issuance under Equity Compensation

We did not issue any shares under our equity compensation

plan in the fiscal year of 2024.

We issued an aggregate of 6,950,000 shares under

our equity compensation plan in the fiscal year of 2025.

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity